Authors

Latest:

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Sumanta Kumar Pal, MD, City of Hope

Latest:

Series Wrap-up: Novel Therapies for mRCC

A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.

Sumanta Kumar Pal, MD, City of HopeÂ

Sumanta Kumar Pal, MD, City of HopeÂ Â

Sumer K. Wallace, MD

Latest:

Sentinel Lymph Node Excision Has Value in Endometrial Cancer

Although the therapeutic utility of lymphadenectomy is uncertain, it continues to provide information for staging and helps to guide postoperative adjuvant treatment for patients with endometrial cancer.

Sumit K. Subudhi, MD, PhD

Latest:

Ongoing Clinical Trials in the Metastatic CRPC Setting

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

Sundar Jagannath, MD

Latest:

Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma

Sundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.

Sundar Jagannath, MD, Tisch Cancer Institute

Sung W. Choi, MD

Latest:

Dr. Sung Choi on Vorinostat in GVHD Prevention

Sung W. Choi, MD, Assistant Professor, University of Michigan, discusses the results of a phase I/II trial examining the use of the histone deacetylase (HDAC) inhibitor vorinostat in graft-versus-host disease (GVHD) prevention.

Sunil Verma, MD

Latest:

Dr. Verma Discusses Biosimilars for Trastuzumab

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses the potential role for trastuzumab (Herceptin) biosimilars.

Sunil Verma, MD, MSEd, FRCPC

Latest:

Dr. Verma Discusses Clinical Trial Endpoints in Metastatic Breast Cancer

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in early-stage breast cancer.

Sunil Verma, MD, MSEd, FRCPC, University of Calgary

Supriya G. Mohile, MD, MS

Latest:

Dr. Mohile On Prostate Cancer in Elderly Patients

Dr. Supriya Mohile from the University of Rochester Medical Center Discusses Prostate Cancer in Elderly Patients

Supriya Gupta Mohile, MD, MS

Latest:

Dr. Mohile on Implementing Geriatric Assessment into Cancer Care

Supriya Gupta Mohile, MD, MS, professor of medicine and surgery, James Wilmot Cancer Institute, director, Geriatric Oncology Clinic, University of Rochester, discusses implementing geriatric assessments into cancer care.

Surabhi Dangi-Garimella, PhD

Latest:

Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL

Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.

Surabhi Dangi-Garimella, PhD, from AJMC.com

Latest:

Trial Backs 50-Gene Test in Neoadjuvant Setting

Neoadjuvant chemotherapy for women diagnosed with breast cancer can help shrink a tumor prior to surgery, which can make the procedure minimally invasive and potentially influence prognosis.

Surendra Srinivas Shastri, MD

Latest:

Dr. Shastri on Vinegar as a Cervical Cancer Screening Tool

Surendra Srinivas Shastri, MD, Professor, Preventive Oncology, Tata Memorial Hospital, Mumbai, India, discusses the results of a study looking at vinegar (acetic acid) as a cervical cancer screening tool.

Suresh A. Ramalingam, MD

Latest:

Dr. Ramalingam on the Results of an Exploratory Analysis of the CheckMate 227 Trial in NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the results of an exploratory analysis of the ongoing phase 3 CheckMate 227 trial in advanced non–small cell lung cancer.

Suresh Ramalingam, MD,

Latest:

Dr. Ramalingam on Investigating Osimertinib Combination Approaches in NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO, discusses ongoing trials investigating osimertinib combination approaches in non-small cell lung cancer.

Suresh Ramalingam, MD, Winship Cancer Institute Emory University

Latest:

Dr. Ramalingam on the Clinical Examination of Patritumab Deruxtecan in NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the exploration of patritumab deruxtecan in non–small cell lung cancer.